scholarly journals Association Of Low Height With Low Weight Presented During Chemotherapy Treatment In Pediatric Patients In Remission Of Acute Lymphoblastic Leukemia (ALL)

2020 ◽  
Vol 6 (5) ◽  
pp. 1-5
Author(s):  
Ismael Lares-Asseff ◽  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Pediatric Cancer ◽  
Malignant Disease ◽  
Pediatric Patients ◽  
Lymphoblastic Leukemia ◽  
White Blood Cells ◽  
Developed Countries ◽  
Chemotherapy Treatment ◽  
Nutritional Factors ◽  
Low Weight

Childhood Acute Lymphoblastic Leukemia (ALL) is the most common pediatric cancer in the world, but especially in developed countries, it is a malignant disease of the white blood cells with a multifactorial etiology that involves an interaction of environmental, genetic and nutritional factors . It is estimated that more than 60% of the patients diagnosed with ALL are children under 15 years of age, with an incidence at 2-5 years.

Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene

2017 ◽  
Vol 32 (1) ◽  
pp. 1-9 ◽  
Author(s):  
Maria Lopez-Santillan ◽  
Leire Iparraguirre ◽  
Idoia Martin-Guerrero ◽  
Angela Gutierrez-Camino ◽  
Africa Garcia-Orad
Keyword(s):  
Treatment Outcome ◽  
Acute Lymphoblastic Leukemia ◽  
Pediatric Cancer ◽  
Lymphoblastic Leukemia ◽  
Antineoplastic Agent ◽  
Developed Countries ◽  
Hypersensitivity Reactions ◽  
Discontinuation Of Treatment ◽  
Antileukemic Effect ◽  
Asparaginase Activity

AbstractAcute lymphoblastic leukemia (ALL) is a major pediatric cancer in developed countries. Although treatment outcome has improved owing to advances in chemotherapy, there is still a group of patients who experience severe adverse events. L-Asparaginase is an effective antineoplastic agent used in chemotherapy of ALL. Despite its indisputable indication, hypersensitivity reactions are common. In those cases, discontinuation of treatment is usually needed and anti-asparaginase antibody production may also attenuate asparaginase activity, compromising its antileukemic effect. Till now, six pharmacogenetic studies have been performed in order to elucidate possible genetic predisposition for inter-individual differences in asparaginase hypersensitivity. In this review we have summarized the results of those studies which describe the involvement of four different genes, being polymorphisms in the glutamate receptor, ionotropic, AMPA 1 (

scholarly journals Telomerase (hTERT) Overexpression Reveals a Promising Prognostic Biomarker and Therapeutical Target in Different Clinical Subtypes of Pediatric Acute Lymphoblastic Leukaemia

Genes ◽  
2021 ◽  
Vol 12 (10) ◽  
pp. 1632
Author(s):  
Beatriz Maria Dias Nogueira ◽  
Laudreísa da Costa Pantoja ◽  
Emerson Lucena da Silva ◽  
Fernando Augusto Rodrigues Mello Júnior ◽  
Eliel Barbosa Teixeira ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Pediatric Patients ◽  
Lymphoblastic Leukemia ◽  
White Blood Cells ◽  
Gene Fusions ◽  
Htert Expression ◽  
Clinical Variables ◽  
Htert Gene ◽  
Promising Target ◽  
Human Telomerase

Acute Lymphoblastic Leukemia (ALL) is a neoplasm of the hematopoietic system defined as a clonal expansion of an abnormal lymphoid precursor cell. It mostly affects children under five years of age and is the most common tumor to afflict pediatric patients. The expression of the human telomerase gene (hTERT) in patients with ALL has been studied as a biomarker and could become a new therapeutic target. We evaluate the role of hTERT gene expression in ALL pediatric patients, through quantitative real-time PCR technique, and the possible correlation between hTERT expression and clinical variables: gender, age, white blood cells (WBC), gene fusions, and immunophenotyping. The analysis between healthy controls and ALL patients (N = 244) was statistically significant (p < 0.001), demonstrating hTERT overexpression in these patients. In comparison with the usual set of clinical variables, the data were not statistically significant (p > 0.05), indicating that hTERT is equally overexpressed among patients regardless of gender, age, gene fusions, and immunophenotyping. Moreover, patients who presented a higher hTERT expression level had a significant (p < 0.0001) lower overall survival rate. In summary, hTERT expression emerges as an important molecular pathway in leukemogenesis regardless patient’s clinical variables, thus, the data here presented pointed it as a valuable biomarker in pediatric acute lymphoblastic leukemia and a promising target for new therapeutic and prognostic measures.

scholarly journals Renal involvement at diagnosis of pediatric acute lymphoblastic leukemia

2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Mayerly Prada-Rico ◽  
Carmen Inés Rodríguez-Cuellar ◽  
Lucy Natalia Arteaga Aya ◽  
Claudia Lorena Nuñez Chates ◽  
Sandra Patricia Garces Sterling ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Acute Leukemia ◽  
Pediatric Patients ◽  
Lymphoblastic Leukemia ◽  
Renal Involvement ◽  
Signs And Symptoms ◽  
Case Review ◽  
Chemotherapy Treatment ◽  
Retrospective Case ◽  
Extrarenal Manifestations

Acute leukemia is the most common type of cancer in pediatric patients. This type of cancer accounts for a third of all childhood cancer cases. More than half of pediatric acute leukemia patients show signs and symptoms such as hepatomegaly, splenomegaly, pallor, fever and bruising at the time of diagnosis. In early stages of acute lymphoblastic leukemia (ALL), nephromegaly and other renal manifestations such as high blood pressure (HBP) and renal failure are uncommon, although renal infiltration and nephromegaly are common in advanced-stage pediatric patients. This is a retrospective case review with a critical appraisal of the existing evidence from the literature. We present a clinical case of a child with HBP associated with bilateral nephromegaly which resolved after chemotherapy treatment. This patient presented with HBP that required pharmacological treatment, likely owing to nephromegaly. All HBP secondary causes were rejected. Nephromegaly was resolved after chemotherapy treatment, and antihypertensive medication was discontinued. Nephromegaly and HBP are rare manifestations of ALL debut in pediatrics. The present case report illustrates this unusual combination and Suggests clinicians to consider malignancy as its causal factor, especially if the symptoms are accompanied by other suggestive extrarenal manifestations.

Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia

2021 ◽  
pp. 1-12
Author(s):  
Katherine A. Dunn ◽  
Zara Forbrigger ◽  
Jessica Connors ◽  
Mushfiqur Rahman ◽  
Alejandro Cohen ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Pediatric Patients ◽  
Lymphoblastic Leukemia ◽  
Bacterial Gene

Screening for asymptomatic diabetes and metabolic comorbidities in pediatric patients during therapy for acute lymphoblastic leukemia

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Valerie Larouche ◽  
Caroline Bellavance ◽  
Pauline Tibout ◽  
Sebastien Bergeron ◽  
David Simonyan ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Acute Lymphoblastic Leukemia ◽  
Pediatric Patients ◽  
Lymphoblastic Leukemia ◽  
Fasting Blood Glucose ◽  
Metabolic Disturbances ◽  
Metabolic Complications ◽  
Glucose Levels ◽  
Oncology Unit ◽  
Hba1c Levels

Abstract Objectives Chronic metabolic disturbances related to cancer treatment are well reported among survivors of pediatric acute lymphoblastic leukemia (ALL). However, few studies have investigated the incidence of these complications during the phase of chemotherapy. We evaluated the incidence of acute metabolic complications occurring during therapy in our cohort of patients diagnosed with ALL. Methods A prospective study involving 50 ALL pediatric patients diagnosed and treated between 2012 and 2016 in our oncology unit. We collected weight, blood pressure, fasting plasma glucose and hemoglobin A1C (HBA1c) levels during the two years of therapy. Results Obesity and overweight occurred in 43 and 25%, respectively among patients and have been reached at 12 months of chemotherapy. About 26% of the patients developed high blood pressure and 14% experienced hyperglycemias without meeting diabetes criteria. There was a significant decrease of HBA1c levels between the beginning and the end of therapy (p<0.0001). Conclusions Increase of body mass index in our ALL pediatric patients occurred during the first months of therapy and plateaued after a year of treatment. We should target this population for early obesity prevention. HbA1c levels measured during therapy did not reveal diabetes criteria. Hence, fasting blood glucose levels are sufficient to monitor ALL pediatric patients’ glycemia.

Sign in / Sign up

Export Citation Format

Share Document